Phase I study on patients with oxi refractory/intolerant KRAS mutant CRC
coloCan
Member Posts: 1,944 Member
announced this date by Calgary, Canada-based Oncolytics Biotech, which will consist of FOLFIRI (Leucovorin,5FU and Irinotecan)with this new thing called Reolysin (REO). For more info see www.prnewsire.com or
rttnews.com
Hope this helps someone
rttnews.com
Hope this helps someone
0
Discussion Boards
- 119.2K All Discussion Boards
- 5 CSN Information
- 5 Welcome to CSN
- 119.3K Cancer specific
- 2.7K Anal Cancer
- 424 Bladder Cancer
- 297 Bone Cancers
- 1.6K Brain Cancer
- 28.1K Breast Cancer
- 376 Childhood Cancers
- 27.6K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.6K Head and Neck Cancer
- 6.2K Kidney Cancer
- 643 Leukemia
- 765 Liver Cancer
- 4K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 215 Multiple Myeloma
- 7.1K Ovarian Cancer
- 34 Pancreatic Cancer
- 477 Peritoneal Cancer
- 5K Prostate Cancer
- 1.1K Rare and Other Cancers
- 521 Sarcoma
- 693 Skin Cancer
- 633 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.7K Uterine Cancer
- 6.2K Other Discussion Boards